Indaptus Therapeutics Inc

NASDAQ:INDPUnited States

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Contact Information

Headquarters

3 Columbus Circle, 15Th FloorNEW YORK, NY, United States 10019

Phone

646-427-2727

Fax

---

Executives

Independent Non-Executive Chairman of the Board

Roger Pomerantz

Chief Executive Officer, Director

Jeffrey Meckler

Chief Financial Officer, Treasurer, Secretary

Nir Sassi

Chief Operating Officer

Walt Linscott

Chief Scientific Officer, Director

Michael Newman